Robert J. Hopkins, MD, MPH & TM, FACP, FIDSA, is a highly regarded medical and research professional in infectious diseases with over 25 years of industry experience
Margia Argüello Appointed as Sr. Business Development Manager, BioHealth and Life Sciences, Office of Strategic Industries and Entrepreneurship at Maryland Department of Commerce
The Maryland Department of Commerce has appointed Margia Argüello as Sr. Business Development Manager, BioHealth and Life Sciences, Office of Strategic Industries and Entrepreneurship. She has been tasked with cultivating and coordinating opportunities to expand, retain, and attract biohealth and life sciences businesses in Maryland. This includes the development and implementation of programs and initiatives to address the needs of the industry, such as talent attraction and workforce development; capital investment activity expansion; as well as technology transfer and commercialization strategies. Margia will also be working closely with entrepreneurs, start-ups, and early-stage life sciences companies to navigate the resources available to them throughout the Maryland life sciences ecosystem.
Judy Costello Appointed as Special Projects Manager, Office of the County Executive at Montgomery County, Maryland
The Office of the County Executive at Montgomery County, Maryland recently announced the appointment of Judy Costello as Special Projects Manager. As Special Projects Manager, Judy supports a wide range of business and economic development-related projects (i.e., business/large employer recruitment and retention, education and workforce, small business and innovation, climate change, and transportation). Her focus covers multiple industries within the County.
miRecule, Inc. (“miRecule”), an emerging biotech company focused on the development of cutting-edge RNA therapeutics, announced the hiring of Fu-An Kang, Ph.D. to serve as its Vice President of Research. Dr. Kang joins miRecule after serving for 6 years as the Senior Director of Chemistry at Abzena, a leading chemistry, biologics and antibody-drug conjugate (ADC) research organization.
Early Charm, a venture studio that converts science to business, today announced the hiring of Dan Keeley to lead Lankenau Ventures, a new joint venture with Early Charm that aims to accelerate development and commercialization of medical inventions conceived by frontline healthcare workers.
Longeveron Announces the Hiring of Dan Gincel, Ph.D., as Senior Vice President, Strategic Collaborations & Scientific Affairs
Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced the hiring of Dan Gincel, Ph.D. as Senior Vice President, Strategic Collaborations & Scientific Affairs.
Commission Appoints Amritha Jaishankar, Ph.D. as Executive Director, Maryland Stem Cell Research Fund (MSCRF)
The Maryland Stem Cell Research Commission (Commission) announces the appointment of Amritha Jaishankar, PhD as Executive Director, Maryland Stem Cell Research Fund (MSCRF).
Leading coronavirus scientist, Kizzmekia S. Corbett, to join Harvard T.H. Chan School of Public Health to continue vaccine development research
Leading coronavirus scientist Kizzmekia S. Corbett is joining Harvard Chan School as an assistant professor to continue vaccine development research.
WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocytes (MILs®) for cancer immunotherapy, today announced the appointment of Co-Founder Kimberly Noonan, PhD, MPH, to Executive Vice President, Chief Science & Technology Officer. In this role, Dr. Noonan’s leadership will expand to include WindMIL’s efforts in manufacturing and manufacturing science and technology (MS&T).
Dr. Jürgen Schumacher is an internationally recognized German entrepreneur with more than 35 years of expertise in the biotech industry. Dr. Schumacher co-founded Qiagen AG, one of Germany’s largest biotechnology companies, NewLab Bioquality AG, which was acquired by Charles River Laboratories International Inc., BiBiTech and Algiax Pharmaceuticals. Dr. Schumacher advises and invests in promising biotech business models.